DrugMar 8, 2023
Pravastatin Sodium Tablets USP, 10 mg recall — FDA D-0421-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
10,685drug recall records
953FDA Class I records
8firms with 5+ records
Aidapak Services, LLC537 records
Database records
Records — page 74
10,685 detailed records are currently available in this category.
DrugMar 8, 2023
Pravastatin Sodium Tablets USP 20 mg recall — FDA D-0422-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 200 microgram/mL recall — FDA D-0345-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 137 microgram/mL recall — FDA D-0343-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 500 mL Excel Plus Container recall — FDA D-0347-2023
Lack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL Plus IV Container product due to the possibility of an incomplete seal that may…
Class IIFDA: CompletedB. Braun Medical Inc.
DrugMar 1, 2023
SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 1000 mL Excel Plus Container recall — FDA D-0346-2023
Lack of sterility assurance: Recall of certain batches of 0.9% Sodium Chloride for Injection USP in EXCEL Plus IV Container product due to the possibility of an incomplete seal that may…
Class IIFDA: CompletedB. Braun Medical Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 75 microgram/mL recall — FDA D-0340-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 150 microgram/mL recall — FDA D-0344-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 62.5 microgram/mL recall — FDA D-0339-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle recall — FDA D-0330-2023
Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.
Class IIFDA: OngoingDr. Reddy's Laboratories, Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL recall — FDA D-0334-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL recall — FDA D-0342-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL recall — FDA D-0336-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL recall — FDA D-0333-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL recall — FDA D-0341-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL recall — FDA D-0332-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL recall — FDA D-0331-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL recall — FDA D-0337-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
Dermoplast FIRST AID ANTIBACTERIAL SPRAY recall — FDA D-0329-2023
Subpotent Drug: Low assay observed in one of the two active ingredients during stability testing.
Class IIIFDA: TerminatedAdvantice Health, LLC
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL recall — FDA D-0338-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL recall — FDA D-0335-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugFeb 22, 2023
Sentara Infusion Services HYDROMORPHONE (a) 1MG/ML IN NS, 50ML, 75 ML, 100ML, 175ML recall — FDA D-0296-2023
Lack of sterility assurance
Class IIFDA: TerminatedSentara Infusion Services
DrugFeb 22, 2023
Sentara Infusion Services TPN (a) 95GM/AA, 385/DEX, 50GM/LIP 1800ML, (b)TPN AA:100GM recall — FDA D-0321-2023
Lack of sterility assurance
Class IIFDA: TerminatedSentara Infusion Services
DrugFeb 22, 2023
Sentara Infusion Services TPN (a) 100GM/AA, 285GM/DEX, (b)55GM/LIP 2300ML, (c)55GM/AA recall — FDA D-0318-2023
Lack of sterility assurance
Class IIFDA: TerminatedSentara Infusion Services
How to use this drug recall index
A drug recall record can include the reason for recall, firm, status, distribution pattern, quantity and FDA classification. This site does not provide medical advice; it organizes public recall information and links users back to official sources.
Recall Lookup USA keeps the last complete source record available when an official data service is temporarily unavailable. When a source provides only a few fields, we show only those known facts rather than padding the page with generic text.
What the database can and cannot tell you
This database is designed for discovery and reference. It can help you locate a relevant recall record, identify the recalling firm or NHTSA campaign, compare dates and classifications, and follow the official source. It is not a substitute for a VIN-specific NHTSA check, a manufacturer notice, medical advice or instructions issued by the recalling company.